Rajesh, Y <br/><br/>
Targeting NFE2L2, a transcription factor upstream of MMP-2: A potential therapeutic strategy for temozolomide resistant glioblastoma.  [electronic resource] 

 -  Biochemical pharmacology  06 2019 
 - 1-16 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1873-2968 
<br/><br/><label>Standard No.: </label>10.1016/j.bcp.2019.03.025  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antineoplastic Agents, Alkylating--administration & dosage<br/>Base Sequence<br/>Brain Neoplasms--drug therapy<br/>Cell Line, Tumor<br/>Cell Proliferation--drug effects<br/>Dose-Response Relationship, Drug<br/>Drug Delivery Systems--methods<br/>Drug Resistance, Neoplasm--drug effects<br/>Glioblastoma--drug therapy<br/>Humans<br/>Matrix Metalloproteinase 2--genetics<br/>Mice, Nude<br/>NF-E2-Related Factor 2--antagonists & inhibitors<br/>Protein Structure, Tertiary<br/>Temozolomide--administration & dosage<br/>Transcription Factors--antagonists & inhibitors